ROSEN, A RESPECTED INVESTOR ADVICE, is supported by AbbVie Inc.

NEW YORK, April 9, 2022 (GLOBE NEWSWIRE) –

WHY: Rosen Law Firm, a global law firm for investors’ rights, announces that a class action lawsuit has been filed on behalf of buyers of AbbVie Inc. securities. (NYSE: ABBV) between 30 April 2021 and 31 August 2021 inclusive (“Class Period”). A class action has already been filed. If you want to serve as the main prosecutor, you must go to court no later than 6.6.2022.

SO WHAT: If you purchased AbbVie securities during the Class Period, you may be entitled to compensation without paying any fees or costs from your own pocket through a replacement fee agreement.

WHAT TO DO NEXT: To join AbbVie’s class action, go to https://rosenlegal.com/submit-form/?case_id=5119 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email at pkim@rosenlegal.com or case@rosenlegal.com for class action information. A class action has already been filed. If you want to serve as the main prosecutor, you must go to court no later than 6.6.2022. The lead plaintiff is the representative party acting on behalf of the other members of the class in litigation.

WHY ROSEN’S LAW: We encourage investors to choose a qualified advisor with a record of success in leadership positions. Notifying companies often do not have comparable experience, resources or any meaningful partnership recognition. Be wise when choosing an advisor. Rosen, a law firm, represents investors around the world, focusing its practice on securities class actions and shareholder derivatives litigation. The law firm Rosen has achieved the largest class action lawsuit against a Chinese company in history. In 2017, the law firm Rosen ranked 1st according to ISS Securities Class Action Services in the number of class actions in the field of securities. The company has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars from investors. In 2019 alone, the company secured more than $ 438 million for investors. In 2020, Laurence Rosen’s founding partner was named by the law360 as the Plaintiff’s Titan. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the defendants made false and / or misleading statements during the Class Period and / or did not disclose that: (1) the safety concerns of Xeljanz and Xeljanz XR related to Rinvoq and other Janus kinase (JAK) inhibitors; (2) As a result, it was likely that the FDA would require additional safety warnings for Rinvoq and delay the approval of additional treatment indications for Rinvoq. and (3) the defendants’ statements about AbbVie’s business, operations and prospects therefore lacked an adequate basis. When the details came to the market, the lawsuit alleged that the investors had suffered damage.

To join AbbVie’s class action, go to https://rosenlegal.com/submit-form/?case_id=5119 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email at pkim@rosenlegal.com or case@rosenlegal.com for class action information.

No class has been certified. Until the class is certified, you will not be represented by a lawyer unless you retain one. You can choose a consultant of your choice. You can also remain an absent member of the class and do nothing at this point. The investor’s ability to participate in any potential future recovery does not depend on whether he will serve as the lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer Advertising. Previous results do not guarantee a similar result.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, PA
275 Madison Avenue, 40th floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
case@rosenlegal.com
www.rosenlegal.com

Leave a Comment